Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Thomas Website

Anish Thomas, M.D.

Selected Publications

1)  Kelly RJ, Thomas A, Rajan A, Chun G, Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, Poondru S, Van Sant C, Keating A, Steinberg SM, Figg W, Giaccone G.
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.
Ann. Oncol. 24: 2601-6, 2013.
2)  Thomas A, Mena E, Kurdziel K, Venzon D, Khozin S, Berman AW, Choyke P, Szabo E, Rajan A, Giaccone G.
18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors.
Clin. Cancer Res. 19: 1487-93, 2013.
3)  Thomas A, Shanbhag S, Haglund K, Berman A, Jakopovic M, Szabo E, Arai A, Schrump DS, Kwong KF, Rajan A, Giaccone G.
Characterization and management of cardiac involvement of thymic epithelial tumors.
J Thorac Oncol. 8: 246-9, 2013.
4)  Thomas A, Hassan R.
Immunotherapies for non-small-cell lung cancer and mesothelioma.
Lancet Oncol. 13: e301-10, 2012.
5)  Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O.
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood. 119: 2731-7, 2012.
6)  Landgren O, Thomas A, Mailankody S.
Myeloma and second primary cancers.
N. Engl. J. Med. 365: 2241-2, 2011.
7)  Thomas A, Xi L, Carter CA, Rajan A, Khozin S, Szabo E, Dennis PA, Giaccone G, Raffeld M.
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.
Clin Lung Cancer. 14: 452-6, 2013.
8)  Hassan R, Miller AC, Sharon E, Thomas A, Reynolds JC, Ling A, Kreitman RJ, Miettinen MM, Steinberg SM, Fowler DH, Pastan I.
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Sci Transl Med. 5: 208ra147, 2013.
9)  Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B, Szabo E, Lee MJ, Trepel JB, Browne SK, Rosen LB, Yu Y, Steinberg SM, Chen HX, Riely GJ, Giaccone G.
Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial.
Lancet Oncol. 15: 191-200, 2014.
10)  Jakopovic M, Thomas A, Lopez-Chavez A.
From platinum compounds to targeted therapies in advanced thoracic malignancies.
Anticancer Res. 34: 477-82, 2014.
Click Here to View Expanded Bibliography.

This page was last updated on 3/7/2014.